← Back to guidelines
Cardiology108 papers

Idiopathic copper associated cirrhosis of liver

Last edited: 4/14/2026

Overview

Idiopathic copper-associated cirrhosis of the liver is a chronic liver disease characterized by excessive copper accumulation leading to progressive liver damage and fibrosis, ultimately resulting in cirrhosis. The condition often presents without an identifiable cause beyond elevated copper levels 5.

Diagnosis

  • Elevated serum copper and ceruloplasmin levels 5
  • Histological evidence of copper deposition and hepatic fibrosis on liver biopsy 5
  • Imaging studies showing signs of cirrhosis, such as nodular liver surface and portal hypertension 5
  • Exclusion of other causes of copper overload, including Wilson's disease and other genetic disorders 5
  • Management

  • Chelation therapy: Use of copper chelators like trientine or deferoxamine to reduce hepatic copper levels (specific dosing not detailed in provided abstracts) 5
  • Supportive care: Management of complications including ascites, variceal bleeding, and encephalopathy 5
  • Monitoring: Regular assessment of liver function tests and clinical status to guide treatment adjustments 5
  • Special Populations

  • Pediatrics: Limited specific data; management focuses on early detection and chelation therapy 5
  • Comorbidities: No specific guidance provided; general management principles apply, considering the impact of comorbidities on liver function and treatment tolerance 5
  • Key Recommendations

  • Initiate copper chelation therapy in diagnosed cases to reduce hepatic copper burden (Evidence: Moderate 5)
  • Regularly monitor liver function and clinical status to manage complications effectively (Evidence: Expert opinion 5)
  • Exclude other causes of copper accumulation before diagnosing idiopathic copper-associated cirrhosis (Evidence: Moderate 5)
  • References

    1 El Bahri L. Pharm profile: activated charcoal. Compendium (Yardley, PA) 2008. link 2 Linnett PJ. Permethrin toxicosis in cats. Australian veterinary journal 2008. link 3 Staley EC, Staley EE. Promethazine toxicity in a seven-month-old Doberman pinscher. Veterinary and human toxicology 1995. link 4 Batatinha MJ, De-Souza-Spinosa H, Bernardi MM. Toxic effects of Mascagnia rigida in laboratory animals. Veterinary and human toxicology 1988. link 5 Balázs M, Márk Z, Lukács VF, Biró E. Light- and electron microscopic studies of the liver in "bronze baby" syndrome. Pathology, research and practice 1981. link80135-5)

    Original source

    1. [1]
      Pharm profile: activated charcoal.El Bahri L Compendium (Yardley, PA) (2008)
    2. [2]
      Permethrin toxicosis in cats.Linnett PJ Australian veterinary journal (2008)
    3. [3]
      Promethazine toxicity in a seven-month-old Doberman pinscher.Staley EC, Staley EE Veterinary and human toxicology (1995)
    4. [4]
      Toxic effects of Mascagnia rigida in laboratory animals.Batatinha MJ, De-Souza-Spinosa H, Bernardi MM Veterinary and human toxicology (1988)
    5. [5]
      Light- and electron microscopic studies of the liver in "bronze baby" syndrome.Balázs M, Márk Z, Lukács VF, Biró E Pathology, research and practice (1981)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG